×
COSCIENS Biopharma EBITDA 2010-2025 | CSCI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
COSCIENS Biopharma ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
COSCIENS Biopharma EBITDA 2010-2025 | CSCI
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
COSCIENS Biopharma ebitda from 2010 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$251.1B
Amgen (AMGN)
$158.1B
Gilead Sciences (GILD)
$142.4B
Vertex Pharmaceuticals (VRTX)
$101.3B
Bristol Myers Squibb (BMY)
$97.5B
GSK (GSK)
$81.9B
CSL (CSLLY)
$68.2B
Regeneron Pharmaceuticals (REGN)
$62.5B
Alnylam Pharmaceuticals (ALNY)
$59.6B
Argenex SE (ARGX)
$40.4B
Insmed (INSM)
$27.9B
BioNTech SE (BNTX)
$26.7B
Royalty Pharma (RPRX)
$21.2B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.6B
Genmab (GNMSF)
$16.1B
Genmab (GMAB)
$15.8B
Illumina (ILMN)
$15.6B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$11.1B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
Moderna (MRNA)
$10.6B
Exelixis (EXEL)
$10.4B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Exact Sciences (EXAS)
$9B
Bio-Techne Corp (TECH)
$8.9B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8.1B